Peptides for Neuroprotection & Brain Injury Recovery

How peptide Targets Peptides for Neuroprotection

Neuroprotective peptides work through several overlapping mechanisms. Cerebrolysin, a porcine brain-derived peptide mixture, has been studied in over 150 clinical trials for stroke, traumatic brain injury (TBI), and vascular dementia. It contains neurotrophic fragments that mimic the activity of BDNF, GDNF, and NGF — promoting neuronal survival, reducing apoptosis, and supporting synaptic remodeling in damaged tissue. Semax, a synthetic ACTH(4-10) analogue developed in Russia, upregulates BDNF expression and has demonstrated anxiolytic and cognitive-enhancing properties in both animal models and small human trials. Dihexa, an angiotensin IV analogue, is among the most potent procognitive agents identified in preclinical research — it activates hepatocyte growth factor (HGF/c-Met) signaling at picomolar concentrations, promoting synaptogenesis and dendritic spine formation in animal models of cognitive impairment.

Selank, a tuftsin analogue, modulates IL-6, affects enkephalin metabolism, and has shown neuroprotective and anxiolytic effects in Russian clinical studies, though Western replication remains limited. BPC-157, primarily known for gut and musculoskeletal healing, has emerging preclinical evidence for neuroprotection — it appears to modulate dopaminergic and serotonergic systems and has shown benefit in rodent models of traumatic brain injury, stroke, and neurotoxin exposure.

The honest picture: Cerebrolysin has the strongest clinical evidence, though meta-analyses show mixed results for functional outcomes in stroke. Semax and Selank are approved medications in Russia but lack large Western RCTs. Dihexa has extraordinary preclinical potency but zero published human trial data. Anyone exploring neuroprotective peptides should understand that this remains an active research area — not an established treatment paradigm.